Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Pierre-Yves Loriers who wrote (639)	10/5/1998 11:22:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 900

Check at the Alza-SEQU deal, Sequ is a direct competitor to Lipo. Sequ competes (and NXTR and Aronex)in the liposome business, including Amphotec the direct competitor of Abelcet. The deal values Sequ at about $200 million dollar based on the Alza stock price (pooling of interest 0.4 share of Alza for each 1 SEQU). Bad news: Alza is a strong marketeer, good sales force. Good news: Lipo is worth at least the same as Alza. Based on an equal deal one could get about $5 for Lipo ? ( if somebody see the future, I will say Elan is a good candidate to acquire Lipo). CAVEAT, this is just wild speculation.

To: Pierre-Yves Loriers who wrote (639)	10/30/1998 5:21:00 PM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 900

The Liposome Company to Commence Phase I Trial for TLC ELL-12 PRINCETON, N.J., Oct. 27 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO - news) is pleased to announce the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for the Company's third product, TLC ELL-12, an anticancer agent. This novel drug acts against tumor cells by a mechanism not shared by any currently available anticancer drug. TLC ELL-12 is a formulation of an ether lipid, L-ET-18-OCH3, which acts as a signal transduction modulator. In the 1980's this molecule was shown to selectively inhibit the growth of cancer cells in vitro as well as in a few patients. However, development of L-ET-18- OCH3 was prohibited by hemolytic, gastrointestinal and other toxicities. Liposome Company scientists have developed a liposomal formulation, which reduces these toxicities yet retains, and in some cases enhances, the tumor- specific killing properties seen in the free ether lipid. In Vitro, TLC ELL-12 has shown potent anticancer activity against drug sensitive and drug resistant cell lines. In Vivo, TLC ELL-12 has shown anticancer activity in mouse models of lung metastasis, primary lung tumors, leukemia and a human prostate tumor. Importantly, unlike most other anticancer drugs, TLC ELL-12 does not cause bone marrow suppression and has shown no negative effects on the gastrointestinal tract. A Phase I clinical trial has been designed to enroll adult patients with advanced solid tumors, including non-small-cell lung, prostate and melanoma. The Company expects to commence this trial by the end of the year.